-
1
-
-
79951848755
-
12 receptor for adenosine diphosphate: congenital and drug-induced defects
-
12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-12.
-
(2011)
Blood
, vol.117
, pp. 2102-2112
-
-
Cattaneo, M.1
-
2
-
-
74549137908
-
New P2Y(12) inhibitors
-
Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-9.
-
(2010)
Circulation
, vol.121
, pp. 171-179
-
-
Cattaneo, M.1
-
3
-
-
77953911457
-
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
-
Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-33.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 919-933
-
-
Bonello, L.1
Tantry, U.S.2
Marcucci, R.3
Blindt, R.4
Angiolillo, D.J.5
Becker, R.6
Bhatt, D.L.7
Cattaneo, M.8
Collet, J.P.9
Cuisset, T.10
Gachet, C.11
Montalescot, G.12
Jennings, L.K.13
Kereiakes, D.14
Sibbing, D.15
Trenk, D.16
van Werkum, J.W.17
Paganelli, F.18
Price, M.J.19
Waksman, R.20
more..
-
4
-
-
34250703278
-
Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
-
Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 1: 230-7.
-
(2007)
J Thromb Haemost
, vol.1
, pp. 230-237
-
-
Cattaneo, M.1
-
5
-
-
80052488174
-
Paraoxonase-1 and clopidogrel efficacy - reply
-
Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 and clopidogrel efficacy - reply. Nat Med 2011; 17: 1042-4.
-
(2011)
Nat Med
, vol.17
, pp. 1042-1044
-
-
Bouman, H.J.1
Schömig, E.2
van Werkum, J.W.3
Velder, J.4
Hackeng, C.M.5
Hirschhäuser, C.6
Waldmann, C.7
Schmalz, H.G.8
ten Berg, J.M.9
Taubert, D.10
-
6
-
-
78651239845
-
Paraoxonase-1 is a major determinant of clopidogrel efficacy
-
Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-6.
-
(2011)
Nat Med
, vol.17
, pp. 110-116
-
-
Bouman, H.J.1
Schömig, E.2
van Werkum, J.W.3
Velder, J.4
Hackeng, C.M.5
Hirschhäuser, C.6
Waldmann, C.7
Schmalz, H.G.8
ten Berg, J.M.9
Taubert, D.10
-
7
-
-
82955240702
-
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
-
Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011; 4: 422-8.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 422-428
-
-
Hulot, J.S.1
Collet, J.P.2
Cayla, G.3
Silvain, J.4
Allanic, F.5
Bellemain-Appaix, A.6
Scott, S.A.7
Montalescot, G.8
-
8
-
-
84856385958
-
Paraoxonase-1 and clopidogrel efficacy
-
Camps J, Joven J, Mackness B, Mackness M, Tawfik D, Draganov D, Costa LG, Paragh G, Seres I, Horke S, James R, Hernández A, Reddy S, Shih D, Navab M, Rochu D, Aviram M. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011; 17: 1041-2.
-
(2011)
Nat Med
, vol.17
, pp. 1041-1042
-
-
Camps, J.1
Joven, J.2
Mackness, B.3
Mackness, M.4
Tawfik, D.5
Draganov, D.6
Costa, L.G.7
Paragh, G.8
Seres, I.9
Horke, S.10
James, R.11
Hernández, A.12
Reddy, S.13
Shih, D.14
Navab, M.15
Rochu, D.16
Aviram, M.17
-
10
-
-
80052436076
-
Paraoxonase-1 and clopidogrel efficacy
-
Cuisset T, Morange PE, Quilici J, Bonnet JL, Gachet C, Alessi MC. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011; 17: 1039.
-
(2011)
Nat Med
, vol.17
, pp. 1039
-
-
Cuisset, T.1
Morange, P.E.2
Quilici, J.3
Bonnet, J.L.4
Gachet, C.5
Alessi, M.C.6
-
11
-
-
80051584505
-
Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study
-
Fontana P, James R, Barazer I, Berdagué P, Schved JF, Rebsamen M, Vuilleumier N, Reny JL. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011; 9: 1664-6.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 1664-1666
-
-
Fontana, P.1
James, R.2
Barazer, I.3
Berdagué, P.4
Schved, J.F.5
Rebsamen, M.6
Vuilleumier, N.7
Reny, J.L.8
-
12
-
-
80052790906
-
Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
-
Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann FJ. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4: 429-36.
-
(2011)
Circ Cardiovasc Genet
, vol.4
, pp. 429-436
-
-
Trenk, D.1
Hochholzer, W.2
Fromm, M.F.3
Zolk, O.4
Valina, C.M.5
Stratz, C.6
Neumann, F.J.7
-
13
-
-
79960012663
-
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
-
Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32: 1605-13.
-
(2011)
Eur Heart J
, vol.32
, pp. 1605-1613
-
-
Sibbing, D.1
Koch, W.2
Massberg, S.3
Byrne, R.A.4
Mehilli, J.5
Schulz, S.6
Mayer, K.7
Bernlochner, I.8
Schömig, A.9
Kastrati, A.10
-
14
-
-
8344231455
-
Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance
-
Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
-
(2004)
Arterioscler Thromb Vasc Biol
, vol.24
, pp. 1980-1987
-
-
Cattaneo, M.1
-
15
-
-
79958110089
-
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
-
Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-83.
-
(2011)
J Am Coll Cardiol
, vol.57
, pp. 2474-2483
-
-
Campo, G.1
Parrinello, G.2
Ferraresi, P.3
Lunghi, B.4
Tebaldi, M.5
Miccoli, M.6
Marchesini, J.7
Bernardi, F.8
Ferrari, R.9
Valgimigli, M.10
-
16
-
-
80052167250
-
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data
-
Brar SS, Ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, Disciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54.
-
(2011)
J Am Coll Cardiol
, vol.58
, pp. 1945-1954
-
-
Brar, S.S.1
Ten Berg, J.2
Marcucci, R.3
Price, M.J.4
Valgimigli, M.5
Kim, H.S.6
Patti, G.7
Breet, N.J.8
Disciascio, G.9
Cuisset, T.10
Dangas, G.11
-
18
-
-
84855466786
-
A Meta-Analysis of Impact of Proton Pump Inhibitors on Antiplatelet Effect of Clopidogrel
-
DOI:
-
Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ. A Meta-Analysis of Impact of Proton Pump Inhibitors on Antiplatelet Effect of Clopidogrel. Cardiovasc Ther 2011; DOI:
-
(2011)
Cardiovasc Ther
-
-
Chen, M.1
Wei, J.F.2
Xu, Y.N.3
Liu, X.J.4
Huang, D.J.5
-
19
-
-
33750079553
-
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin
-
Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-9.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 2508-2509
-
-
Gilard, M.1
Arnaud, B.2
Le Gal, G.3
Abgrall, J.F.4
Boschat, J.5
-
20
-
-
38349065084
-
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
-
Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 256-260
-
-
Gilard, M.1
Arnaud, B.2
Cornily, J.C.3
Le Gal, G.4
Lacut, K.5
Le Calvez, G.6
Mansourati, J.7
Mottier, D.8
Abgrall, J.F.9
Boschat, J.10
-
21
-
-
78650517232
-
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies
-
Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 65-74.
-
(2011)
Clin Pharmacol Ther
, vol.89
, pp. 65-74
-
-
Angiolillo, D.J.1
Gibson, C.M.2
Cheng, S.3
Ollier, C.4
Nicolas, O.5
Bergougnan, L.6
Perrin, L.7
LaCreta, F.P.8
Hurbin, F.9
Dubar, M.10
-
22
-
-
64849087438
-
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
-
Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-9.
-
(2009)
Thromb Haemost
, vol.101
, pp. 714-719
-
-
Sibbing, D.1
Morath, T.2
Stegherr, J.3
Braun, S.4
Vogt, W.5
Hadamitzky, M.6
Schömig, A.7
Kastrati, A.8
von Beckerath, N.9
-
23
-
-
78650174732
-
The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests
-
Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol 2010; 56: 532-9.
-
(2010)
J Cardiovasc Pharmacol
, vol.56
, pp. 532-539
-
-
Gremmel, T.1
Steiner, S.2
Seidinger, D.3
Koppensteiner, R.4
Panzer, S.5
Kopp, C.W.6
-
24
-
-
77953896604
-
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
-
Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-43.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 134-143
-
-
Hulot, J.S.1
Collet, J.P.2
Silvain, J.3
Pena, A.4
Bellemain-Appaix, A.5
Barthélémy, O.6
Cayla, G.7
Beygui, F.8
Montalescot, G.9
-
25
-
-
78349244351
-
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis
-
Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624-41.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 2624-2641
-
-
Siller-Matula, J.M.1
Jilma, B.2
Schrör, K.3
Christ, G.4
Huber, K.5
-
26
-
-
61549124132
-
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
-
Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
-
(2009)
JAMA
, vol.301
, pp. 937-944
-
-
Ho, P.M.1
Maddox, T.M.2
Wang, L.3
Fihn, S.D.4
Jesse, R.L.5
Peterson, E.D.6
Rumsfeld, J.S.7
-
27
-
-
78650739879
-
ACCF/ACG/AHA 2010 Expert Consensus Document o the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
-
ACCF/ACG/AHA.
-
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document o the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 122: 2619-33.
-
(2010)
Circulation
, vol.122
, pp. 2619-2633
-
-
Abraham, N.S.1
Hlatky, M.A.2
Antman, E.M.3
Bhatt, D.L.4
Bjorkman, D.J.5
Clark, C.B.6
Furberg, C.D.7
Johnson, D.A.8
Kahi, C.J.9
Laine, L.10
Mahaffey, K.W.11
Quigley, E.M.12
Scheiman, J.13
Sperling, L.S.14
Tomaselli, G.F.15
-
28
-
-
70249139788
-
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
-
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
-
(2009)
Lancet
, vol.374
, pp. 989-997
-
-
O'Donoghue, M.L.1
Braunwald, E.2
Antman, E.M.3
Murphy, S.A.4
Bates, E.R.5
Rozenman, Y.6
Michelson, A.D.7
Hautvast, R.W.8
Ver Lee, P.N.9
Close, S.L.10
Shen, L.11
Mega, J.L.12
Sabatine, M.S.13
Wiviott, S.D.14
-
29
-
-
77950895115
-
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study
-
Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-45.
-
(2010)
Ann Intern Med
, vol.152
, pp. 337-345
-
-
Ray, W.A.1
Murray, K.T.2
Griffin, M.R.3
Chung, C.P.4
Smalley, W.E.5
Hall, K.6
Daugherty, J.R.7
Kaltenbach, L.A.8
Stein, C.M.9
-
30
-
-
73449122247
-
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome
-
Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-9.
-
(2009)
Circulation
, vol.120
, pp. 2322-2329
-
-
Rassen, J.A.1
Choudhry, N.K.2
Avorn, J.3
Schneeweiss, S.4
-
31
-
-
79951677465
-
Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry
-
Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123: 474-82.
-
(2011)
Circulation
, vol.123
, pp. 474-482
-
-
Simon, T.1
Steg, P.G.2
Gilard, M.3
Blanchard, D.4
Bonello, L.5
Hanssen, M.6
Lardoux, H.7
Coste, P.8
Lefèvre, T.9
Drouet, E.10
Mulak, G.11
Bataille, V.12
Ferrières, J.13
Verstuyft, C.14
Danchin, N.15
-
32
-
-
80053276727
-
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome
-
Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011; 20: 1043-9.
-
(2011)
Pharmacoepidemiol Drug Saf
, vol.20
, pp. 1043-1049
-
-
Hsiao, F.Y.1
Mullins, C.D.2
Wen, Y.W.3
Huang, W.F.4
Chen, P.F.5
Tsai, Y.W.6
-
33
-
-
78149487926
-
Clopidogrel with or without omeprazole in coronary artery disease
-
COGENT Investigators.
-
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-17.
-
(2010)
N Engl J Med
, vol.363
, pp. 1909-1917
-
-
Bhatt, D.L.1
Cryer, B.L.2
Contant, C.F.3
Cohen, M.4
Lanas, A.5
Schnitzer, T.J.6
Shook, T.L.7
Lapuerta, P.8
Goldsmith, M.A.9
Laine, L.10
Scirica, B.M.11
Murphy, S.A.12
Cannon, C.P.13
-
35
-
-
78049326068
-
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
-
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-30.
-
(2010)
JAMA
, vol.304
, pp. 1821-1830
-
-
Mega, J.L.1
Simon, T.2
Collet, J.P.3
Anderson, J.L.4
Antman, E.M.5
Bliden, K.6
Cannon, C.P.7
Danchin, N.8
Giusti, B.9
Gurbel, P.10
Horne, B.D.11
Hulot, J.S.12
Kastrati, A.13
Montalescot, G.14
Neumann, F.J.15
Shen, L.16
Sibbing, D.17
Steg, P.G.18
Trenk, D.19
Wiviott, S.D.20
more..
-
36
-
-
79957472412
-
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
-
Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011; 11: 199-206.
-
(2011)
Pharmacogenomics J
, vol.11
, pp. 199-206
-
-
Sofi, F.1
Giusti, B.2
Marcucci, R.3
Gori, A.M.4
Abbate, R.5
Gensini, G.F.6
-
37
-
-
84858999257
-
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
-
Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588.
-
(2011)
BMJ
, vol.343
-
-
Bauer, T.1
Bouman, H.J.2
van Werkum, J.W.3
Ford, N.F.4
ten Berg, J.M.5
Taubert, D.6
-
38
-
-
84155167902
-
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
-
Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-8.
-
(2012)
Heart
, vol.98
, pp. 100-108
-
-
Zabalza, M.1
Subirana, I.2
Sala, J.3
Lluis-Ganella, C.4
Lucas, G.5
Tomás, M.6
Masiá, R.7
Marrugat, J.8
Brugada, R.9
Elosua, R.10
-
39
-
-
84555195438
-
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis
-
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306: 2704-14.
-
(2011)
JAMA
, vol.306
, pp. 2704-2714
-
-
Holmes, M.V.1
Perel, P.2
Shah, T.3
Hingorani, A.D.4
Casas, J.P.5
-
40
-
-
34249997024
-
Replicating genotype-phenotype associations
-
NCI-NHGRI Working Group on Replication in Association Studies
-
NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF Jr, Freimer NB, Gerhard DS, Gunter C, Guttmacher AE et al. Replicating genotype-phenotype associations. Nature 2007; 447: 655-60.
-
(2007)
Nature
, vol.447
, pp. 655-660
-
-
Chanock, S.J.1
Manolio, T.2
Boehnke, M.3
Boerwinkle, E.4
Hunter, D.J.5
Thomas, G.6
Hirschhorn, J.N.7
Abecasis, G.8
Altshuler, D.9
Bailey-Wilson, J.E.10
Brooks, L.D.11
Cardon, L.R.12
Daly, M.13
Donnelly, P.14
Fraumeni Jr, J.F.15
Freimer, N.B.16
Gerhard, D.S.17
Gunter, C.18
Guttmacher, A.E.19
-
41
-
-
78049433100
-
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
-
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-14.
-
(2010)
N Engl J Med
, vol.363
, pp. 1704-1714
-
-
Paré, G.1
Mehta, S.R.2
Yusuf, S.3
Anand, S.S.4
Connolly, S.J.5
Hirsh, J.6
Simonsen, K.7
Bhatt, D.L.8
Fox, K.A.9
Eikelboom, J.W.10
-
42
-
-
77958105401
-
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
-
Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-9.
-
(2010)
Lancet
, vol.376
, pp. 1312-1319
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
Shen, L.4
Walker, J.R.5
Simon, T.6
Antman, E.M.7
Braunwald, E.8
Sabatine, M.S.9
-
43
-
-
0034770003
-
The oral anticoagulant saga: past, present, and future
-
Duxbury BM, Poller L. The oral anticoagulant saga: past, present, and future. Clin Appl Thromb Hemost 2001; 7: 269-75.
-
(2001)
Clin Appl Thromb Hemost
, vol.7
, pp. 269-275
-
-
Duxbury, B.M.1
Poller, L.2
-
44
-
-
77950283264
-
Medication adherence in cardiovascular disease
-
Baroletti S, Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation 2010; 121: 1455-8.
-
(2010)
Circulation
, vol.121
, pp. 1455-1458
-
-
Baroletti, S.1
Dell'Orfano, H.2
-
45
-
-
4644308426
-
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
-
Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 3(Suppl): 188S-203S.
-
(2004)
Chest
, vol.3
, Issue.SUPPL.
-
-
Hirsh, J.1
Raschke, R.2
-
46
-
-
58249142988
-
Methods for the measurement of platelet function
-
Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009; 3(Suppl): 20A-6A.
-
(2009)
Am J Cardiol
, vol.3
, Issue.SUPPL.
-
-
Michelson, A.D.1
-
47
-
-
77249098703
-
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting
-
Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 2010; 103: 39-45.
-
(2010)
Arch Cardiovasc Dis
, vol.103
, pp. 39-45
-
-
Cuisset, T.1
Frere, C.2
Poyet, R.3
Quilici, J.4
Gaborit, B.5
Bali, L.6
Brissy, O.7
Lambert, M.8
Morange, P.E.9
Alessi, M.C.10
Bonnet, J.L.11
-
48
-
-
62449095155
-
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation
-
Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-9.
-
(2009)
Thromb Haemost
, vol.101
, pp. 333-339
-
-
Gremmel, T.1
Steiner, S.2
Seidinger, D.3
Koppensteiner, R.4
Panzer, S.5
Kopp, C.W.6
-
49
-
-
34548075511
-
Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients
-
Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-47.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1839-1847
-
-
Paniccia, R.1
Antonucci, E.2
Gori, A.M.3
Marcucci, R.4
Giglioli, C.5
Antoniucci, D.6
Gensini, G.F.7
Abbate, R.8
Prisco, D.9
-
50
-
-
77955449383
-
Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients
-
Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-92.
-
(2010)
Thromb Haemost
, vol.104
, pp. 287-292
-
-
Paniccia, R.1
Antonucci, E.2
Maggini, N.3
Miranda, M.4
Gori, A.M.5
Marcucci, R.6
Giusti, B.7
Balzi, D.8
Prisco, D.9
Abbate, R.10
-
51
-
-
77249113768
-
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
-
Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-62.
-
(2010)
JAMA
, vol.303
, pp. 754-762
-
-
Breet, N.J.1
van Werkum, J.W.2
Bouman, H.J.3
Kelder, J.C.4
Ruven, H.J.5
Bal, E.T.6
Deneer, V.H.7
Harmsze, A.M.8
van der Heyden, J.A.9
Rensing, B.J.10
Suttorp, M.J.11
Hackeng, C.M.12
ten Berg, J.M.13
-
52
-
-
77951712355
-
Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention
-
Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010; 56: 839-47.
-
(2010)
Clin Chem
, vol.56
, pp. 839-847
-
-
Madsen, E.H.1
Saw, J.2
Kristensen, S.R.3
Schmidt, E.B.4
Pittendreigh, C.5
Maurer-Spurej, E.6
-
53
-
-
75649097149
-
Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry
-
von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schömig A, Kastrati A. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. Blood Coagul Fibrinolysis 2010; 21: 46-52.
-
(2010)
Blood Coagul Fibrinolysis
, vol.21
, pp. 46-52
-
-
von Beckerath, N.1
Sibbing, D.2
Jawansky, S.3
Braun, S.4
Morath, T.5
Vogt, W.6
Schömig, A.7
Kastrati, A.8
-
54
-
-
83955161719
-
Correlation between Light Transmission Aggregometry, VerifyNow P2Y12, and VASP-P Platelet Reactivity Assays Following Percutaneous Coronary Intervention
-
Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Correlation between Light Transmission Aggregometry, VerifyNow P2Y12, and VASP-P Platelet Reactivity Assays Following Percutaneous Coronary Intervention. J Interv Cardiol 2011; 24: 529-34.
-
(2011)
J Interv Cardiol
, vol.24
, pp. 529-534
-
-
Gaglia, M.A.1
Torguson, R.2
Pakala, R.3
Xue, Z.4
Sardi, G.5
Suddath, W.O.6
Kent, K.M.7
Satler, L.F.8
Pichard, A.D.9
Waksman, R.10
-
55
-
-
77952738970
-
A risk score to predict bleeding in patients with acute coronary syndromes
-
Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55: 2556-66.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2556-2566
-
-
Mehran, R.1
Pocock, S.J.2
Nikolsky, E.3
Clayton, T.4
Dangas, G.D.5
Kirtane, A.J.6
Parise, H.7
Fahy, M.8
Manoukian, S.V.9
Feit, F.10
Ohman, M.E.11
Witzenbichler, B.12
Guagliumi, G.13
Lansky, A.J.14
Stone, G.W.15
-
56
-
-
33747599590
-
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
-
Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82.
-
(2006)
Circulation
, vol.114
, pp. 774-782
-
-
Eikelboom, J.W.1
Mehta, S.R.2
Anand, S.S.3
Xie, C.4
Fox, K.A.5
Yusuf, S.6
-
57
-
-
74449093103
-
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial
-
Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010; 121: 43-51.
-
(2010)
Circulation
, vol.121
, pp. 43-51
-
-
Pocock, S.J.1
Mehran, R.2
Clayton, T.C.3
Nikolsky, E.4
Parise, H.5
Fahy, M.6
Lansky, A.J.7
Bertrand, M.E.8
Lincoff, A.M.9
Moses, J.W.10
Ohman, E.M.11
White, H.D.12
Stone, G.W.13
-
58
-
-
77955603691
-
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window
-
Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-8.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 317-318
-
-
Sibbing, D.1
Steinhubl, S.R.2
Schulz, S.3
Schömig, A.4
Kastrati, A.5
-
59
-
-
70249101426
-
Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH
-
Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 1029
-
-
Cattaneo, M.1
Hayward, C.P.2
Moffat, K.A.3
Pugliano, M.T.4
Liu, Y.5
Michelson, A.D.6
-
60
-
-
78649643870
-
Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry
-
Hayward CP, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder JL. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-63.
-
(2010)
Am J Clin Pathol
, vol.134
, pp. 955-963
-
-
Hayward, C.P.1
Moffat, K.A.2
Raby, A.3
Israels, S.4
Plumhoff, E.5
Flynn, G.6
Zehnder, J.L.7
-
61
-
-
77957985413
-
Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy
-
Arméro S, Camoin Jau L, Omar Aït Mokhtar O, Mancini J, Burignat-Bonello C, Tahirou I, Arques S, Dignat-George F, Paganelli F, Bonello L. Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 2010; 21: 503-7.
-
(2010)
Platelets
, vol.21
, pp. 503-507
-
-
Arméro, S.1
Camoin Jau, L.2
Omar Aït Mokhtar, O.3
Mancini, J.4
Burignat-Bonello, C.5
Tahirou, I.6
Arques, S.7
Dignat-George, F.8
Paganelli, F.9
Bonello, L.10
-
62
-
-
78651082582
-
Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients
-
Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schömig A, Kastrati A, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-12.
-
(2011)
Thromb Haemost
, vol.105
, pp. 107-112
-
-
Jaitner, J.1
Stegherr, J.2
Morath, T.3
Braun, S.4
Bernlochner, I.5
Schömig, A.6
Kastrati, A.7
Sibbing, D.8
-
63
-
-
57549090390
-
Clopidogrel 150mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study
-
Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C. Clopidogrel 150mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1: 631-8.
-
(2008)
JACC Cardiovasc Interv
, vol.1
, pp. 631-638
-
-
Aleil, B.1
Jacquemin, L.2
De Poli, F.3
Zaehringer, M.4
Collet, J.P.5
Montalescot, G.6
Cazenave, J.P.7
Dickele, M.C.8
Monassier, J.P.9
Gachet, C.10
-
64
-
-
0023228517
-
Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death
-
Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-8.
-
(1987)
N Engl J Med
, vol.316
, pp. 1514-1518
-
-
Tofler, G.H.1
Brezinski, D.2
Schafer, A.I.3
Czeisler, C.A.4
Rutherford, J.D.5
Willich, S.N.6
Gleason, R.E.7
Williams, G.H.8
Muller, J.E.9
-
65
-
-
80455149677
-
Diurnal variation in platelet inhibition by clopidogrel
-
Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, Siller-Matula JM, Rosc D, Kubica J. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011; 22: 579-87.
-
(2011)
Platelets
, vol.22
, pp. 579-587
-
-
Kozinski, M.1
Bielis, L.2
Wisniewska-Szmyt, J.3
Boinska, J.4
Stolarek, W.5
Marciniak, A.6
Kubica, A.7
Grabczewska, Z.8
Navarese, E.P.9
Andreotti, F.10
Siller-Matula, J.M.11
Rosc, D.12
Kubica, J.13
-
66
-
-
41249093357
-
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study
-
Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-11.
-
(2008)
J Am Coll Cardiol
, vol.51
, pp. 1404-1411
-
-
Bonello, L.1
Camoin-Jau, L.2
Arques, S.3
Boyer, C.4
Panagides, D.5
Wittenberg, O.6
Simeoni, M.C.7
Barragan, P.8
Dignat-George, F.9
Paganelli, F.10
-
67
-
-
58149476444
-
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
-
Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, Barragan P, Dignat-George F, Paganelli F. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
-
(2009)
Am J Cardiol
, vol.103
, pp. 5-10
-
-
Bonello, L.1
Camoin-Jau, L.2
Armero, S.3
Com, O.4
Arques, S.5
Burignat-Bonello, C.6
Giacomoni, M.P.7
Bonello, R.8
Collet, F.9
Rossi, P.10
Barragan, P.11
Dignat-George, F.12
Paganelli, F.13
-
68
-
-
67649204721
-
Can we override clopidogrel resistance?
-
Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, Funck-Brentano C, Montalescot G. Can we override clopidogrel resistance? Circulation 2009; 119: 2854-7.
-
(2009)
Circulation
, vol.119
, pp. 2854-2857
-
-
Pena, A.1
Collet, J.P.2
Hulot, J.S.3
Silvain, J.4
Barthélémy, O.5
Beygui, F.6
Funck-Brentano, C.7
Montalescot, G.8
-
69
-
-
77955638355
-
ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
-
Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56: 321-41.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 321-341
-
-
Holmes Jr, D.R.1
Dehmer, G.J.2
Kaul, S.3
Leifer, D.4
O'Gara, P.T.5
Stein, C.M.6
-
70
-
-
77958128969
-
Guidelines on myocardial revascularization
-
Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI)
-
Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-55.
-
(2010)
Eur Heart J
, vol.31
, pp. 2501-2555
-
-
Wijns, W.1
Kolh, P.2
Danchin, N.3
Di Mario, C.4
Falk, V.5
Folliguet, T.6
Garg, S.7
Huber, K.8
James, S.9
Knuuti, J.10
Lopez-Sendon, J.11
Marco, J.12
Menicanti, L.13
Ostojic, M.14
Piepoli, M.F.15
Pirlet, C.16
Pomar, J.L.17
Reifart, N.18
-
71
-
-
79952598836
-
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
-
GRAVITAS Investigators.
-
Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-105.
-
(2011)
JAMA
, vol.305
, pp. 1097-1105
-
-
Price, M.J.1
Berger, P.B.2
Teirstein, P.S.3
Tanguay, J.F.4
Angiolillo, D.J.5
Spriggs, D.6
Puri, S.7
Robbins, M.8
Garratt, K.N.9
Bertrand, O.F.10
Stillabower, M.E.11
Aragon, J.R.12
Kandzari, D.E.13
Stinis, C.T.14
Lee, M.S.15
Manoukian, S.V.16
Cannon, C.P.17
Schork, N.J.18
Topol, E.J.19
-
72
-
-
79952611488
-
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial
-
Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 2011; 305: 1136-7.
-
(2011)
JAMA
, vol.305
, pp. 1136-1137
-
-
Gurbel, P.A.1
Tantry, U.S.2
-
73
-
-
77958012405
-
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy
-
3T/2R Investigators.
-
Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56: 1447-55.
-
(2010)
J Am Coll Cardiol
, vol.56
, pp. 1447-1455
-
-
Campo, G.1
Fileti, L.2
de Cesare, N.3
Meliga, E.4
Furgieri, A.5
Russo, F.6
Colangelo, S.7
Brugaletta, S.8
Ferrari, R.9
Valgimigli, M.10
-
74
-
-
80052573217
-
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial
-
Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011; 124: 1132-7.
-
(2011)
Circulation
, vol.124
, pp. 1132-1137
-
-
Price, M.J.1
Angiolillo, D.J.2
Teirstein, P.S.3
Lillie, E.4
Manoukian, S.V.5
Berger, P.B.6
Tanguay, J.F.7
Cannon, C.P.8
Topol, E.J.9
-
75
-
-
80053080512
-
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI
-
Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306: 1215-23.
-
(2011)
JAMA
, vol.306
, pp. 1215-1223
-
-
Parodi, G.1
Marcucci, R.2
Valenti, R.3
Gori, A.M.4
Migliorini, A.5
Giusti, B.6
Buonamici, P.7
Gensini, G.F.8
Abbate, R.9
Antoniucci, D.10
-
76
-
-
84857592172
-
-
FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. ; accessed 3 August
-
FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. ; accessed 3 August 2010.
-
(2010)
-
-
-
77
-
-
77956550527
-
Comparative effectiveness research and personalized medicine: catalyzing or colliding?
-
Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 2010; 28: 905-13.
-
(2010)
Pharmacoeconomics
, vol.28
, pp. 905-913
-
-
Epstein, R.S.1
Teagarden, J.R.2
-
78
-
-
77952591958
-
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading an maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
-
Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading an maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-34.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2427-2434
-
-
Hochholzer, W.1
Trenk, D.2
Fromm, M.F.3
Valina, C.M.4
Stratz, C.5
Bestehorn, H.P.6
Büttner, H.J.7
Neumann, F.J.8
-
79
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
-
(2009)
JAMA
, vol.302
, pp. 849-857
-
-
Shuldiner, A.R.1
O'Connell, J.R.2
Bliden, K.P.3
Gandhi, A.4
Ryan, K.5
Horenstein, R.B.6
Damcott, C.M.7
Pakyz, R.8
Tantry, U.S.9
Gibson, Q.10
Pollin, T.I.11
Post, W.12
Parsa, A.13
Mitchell, B.D.14
Faraday, N.15
Herzog, W.16
Gurbel, P.A.17
-
80
-
-
79960160555
-
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
-
Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, ten Cate H, Hackeng CM, Deneer VH, ten Berg JM. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011; 97: 1239-44.
-
(2011)
Heart
, vol.97
, pp. 1239-1244
-
-
Bouman, H.J.1
Harmsze, A.M.2
van Werkum, J.W.3
Breet, N.J.4
Bergmeijer, T.O.5
ten Cate, H.6
Hackeng, C.M.7
Deneer, V.H.8
ten Berg, J.M.9
-
81
-
-
70350025236
-
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
-
Aleil B, Léon C, Cazenave JP, Gachet C. CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. J Thromb Haemost 2009; 7: 1747-9.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 1747-1749
-
-
Aleil, B.1
Léon, C.2
Cazenave, J.P.3
Gachet, C.4
-
82
-
-
67651173161
-
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
-
TRITON-TIMI 38 Investigators.
-
Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2000; 30: 1753-63.
-
(2000)
Eur Heart J
, vol.30
, pp. 1753-1763
-
-
Michelson, A.D.1
Frelinger 3rd, A.L.2
Braunwald, E.3
Downey, W.E.4
Angiolillo, D.J.5
Xenopoulos, N.P.6
Jakubowski, J.A.7
Li, Y.8
Murphy, S.A.9
Qin, J.10
McCabe, C.H.11
Antman, E.M.12
Wiviott, S.D.13
-
83
-
-
79960603731
-
High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes
-
Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, Peyre JP, Wittenberg O, de Labriolle A, Camilleri E, Cheneau E, Cabassome E, Dignat-George F, Camoin-Jau L, Paganelli F. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467-73.
-
(2011)
J Am Coll Cardiol
, vol.58
, pp. 467-473
-
-
Bonello, L.1
Pansieri, M.2
Mancini, J.3
Bonello, R.4
Maillard, L.5
Barnay, P.6
Rossi, P.7
Ait-Mokhtar, O.8
Jouve, B.9
Collet, F.10
Peyre, J.P.11
Wittenberg, O.12
de Labriolle, A.13
Camilleri, E.14
Cheneau, E.15
Cabassome, E.16
Dignat-George, F.17
Camoin-Jau, L.18
Paganelli, F.19
-
84
-
-
77950508416
-
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study
-
Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-99.
-
(2010)
Circulation
, vol.121
, pp. 1188-1199
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
Antonino, M.J.4
Wei, C.5
Teng, R.6
Rasmussen, L.7
Storey, R.F.8
Nielsen, T.9
Eikelboom, J.W.10
Sabe-Affaki, G.11
Husted, S.12
Kereiakes, D.J.13
Henderson, D.14
Patel, D.V.15
Tantry, U.S.16
|